ArticleAntimicrobial agents and chemotherapy2017
Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Clinical research advances of isavuconazole in the treatment of invasive fungal diseases.Frontiers in cellular and infection microbiology · 2022Pooled it
- Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Translational PBPK Modeling and Exposure-Response Analysis of AT-RvD1 for Treating Sjögren's Disease.Clinical and translational science · 2026Article
- Experience with isavuconazole in lung transplant recipients withJHLT open · 2026Article
- Cerebral Aspergillosis: Diagnostic Challenges, Therapeutic Strategies, and Future Research.CNS drugs · 2026Review
- Non-JHLT open · 2025Review
- Isavuconazole as an optimal treatment option for multiple pathogens induced severe pneumonia in immunocompromised hosts: a case series report.Frontiers in medicine · 2025Article
- Outcomes of Invasive Fungal Infections Treated with Isavuconazole: A Retrospective Review.Pathogens (Basel, Switzerland) · 2024Article
- Approaches for TargetingPathogens (Basel, Switzerland) · 2024Review
- Antifungal drug penetration in soft tissue abscesses: a comparative analysis.The Journal of antimicrobial chemotherapy · 2024Article
- Cerebral Infectious Opportunistic Lesions in a Patient with Acute Myeloid Leukaemia: The Challenge of Diagnosis and Clinical Management.Antibiotics (Basel, Switzerland) · 2024Article
- From Spores to Solutions: A Comprehensive Narrative Review on Mucormycosis.Diagnostics (Basel, Switzerland) · 2024Review
- Case report: Successful combination therapy with isavuconazole and amphotericin B in treatment of disseminatedFrontiers in medicine · 2024Article
- Potential Implication of Azole Persistence in the Treatment Failure of Two Haematological Patients Infected withJournal of fungi (Basel, Switzerland) · 2023Article
- PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris.CPT: pharmacometrics & systems pharmacology · 2023Article
- A physiologically based pharmacokinetic analysis to predict the pharmacokinetics of intravenous isavuconazole in patients with or without hepatic impairment.Antimicrobial agents and chemotherapy · 2023Article
- Osteoarticular Mycoses.Clinical microbiology reviews · 2022Review
- Management of Histoplasmosis by Infectious Disease Physicians.Open forum infectious diseases · 2022Article
- The Role of Isavuconazonium Sulphate for the Treatment of Blastomycosis: A Case Series and Antifungal Susceptibility.Open forum infectious diseases · 2022Article
- Experience of Isavuconazole as a Salvage Therapy in Chronic Pulmonary Fungal Disease.Journal of fungi (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quantitative whole-body autoradiography was used to assess the distribution and tissue penetration of isavuconazole in rats following single and repeated oral-dose administration of radiolabeled isavuconazonium sulfate, the prodrug of isavuconazole. Following a single-dose administration of radiolabeled isavuconazonium sulfate (labeled on the active moiety), radioactivity was detectable within 1 h postdose in 56 of 65 tissue/fluid specimens. The highest maximum concentrations (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.